Tenon Medical, Inc.
For the period ended Jun 30, 2026. Filed Aug 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 13, 2026
TNON$1.74-0.6%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ (Deficit) Equity
Condensed Statements of Stockholders’ (Deficit) Equity (Unaudited)
(In thousands, except share data)
Three months ended June 30, 2026 and 2025:
| Series A Convertible Preferred Stock · Series B Convertible Preferred Stock · Common Stock · Additional Paid-In · Accumulated | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Total | |
| Balance at March 31, 2026 | 204,159 | $2,622 | 86,454 | $452 | 322,754 | $— | $83,599 | $(84,778) | $1,895 |
| Stock-based compensation expense | — | — | — | — | — | — | 412 | — | 412 |
| Release of restricted stock units | — | — | — | — | 24 | — | — | — | — |
| Issuance of common stock to SiVantage upon completion of milestone | — | — | — | — | 7,892 | — | — | — | — |
| Net loss | — | — | — | — | — | — | — | (4,050) | (4,050) |
| Balance at June 30, 2026 | 204,159 | $2,622 | 86,454 | $452 | 330,670 | $— | $84,011 | $(88,828) | $(1,743) |
| Balance at March 31, 2025 | 256,968 | $3,300 | 86,454 | $452 | 216,856 | $— | $77,986 | $(72,362) | $9,376 |
| Stock-based compensation expense | — | — | — | — | — | — | 417 | — | 417 |
| Release of restricted stock units | — | — | — | — | 64 | — | — | — | — |
| Deferred deal costs | — | — | — | — | — | — | (311) | — | (311) |
| Net loss | — | — | — | — | — | — | — | (2,769) | (2,769) |
| Balance at June 30, 2025 | 256,968 | $3,300 | 86,454 | $452 | 216,920 | $— | $78,092 | $(75,131) | $6,713 |
Six months ended June 30, 2026 and 2025:
| Series A Convertible Preferred Stock · Series B Convertible Preferred Stock · Common Stock · Additional Paid-In · Accumulated | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Shares | Amount | Capital | Deficit | Total | |
| Balance at December 31, 2025 | 204,159 | $2,622 | 86,454 | $452 | 310,036 | $— | $83,268 | $(81,302) | $5,040 |
| Stock-based compensation expense | — | — | — | — | — | — | 743 | — | 743 |
| Release of restricted stock units | — | — | — | — | 12,742 | — | — | — | — |
| Issuance of common stock to SiVantage upon completion of milestone | — | — | — | — | 7,892 | — | — | — | — |
| Net loss | — | — | — | — | — | — | — | (7,526) | (7,526) |
| Balance at June 30, 2026 | 204,159 | $2,622 | 86,454 | $452 | 330,670 | $— | $84,011 | $(88,828) | $(1,743) |
| Balance at December 31, 2024 | 256,968 | $3,300 | 86,454 | $452 | 89,680 | $— | $70,965 | $(68,746) | $5,971 |
| Stock-based compensation expense | — | — | — | — | — | — | 1,289 | — | 1,289 |
| Issuance of common stock, pre-funded warrants and warrants under inducement agreement, net of issuance costs | — | — | — | — | 69,877 | — | 2,735 | — | 2,735 |
| Issuance of common stock, pre-funded warrants, and warrants, net of issuance costs | — | — | — | — | 57,286 | — | 3,524 | — | 3,524 |
| Release of restricted stock units | — | — | — | — | 77 | — | — | — | — |
| Deferred financing costs | — | — | — | — | — | — | (421) | — | (421) |
| Net loss | — | — | — | — | — | — | — | (6,385) | (6,385) |
| Balance at June 30, 2025 | 256,968 | $3,300 | 86,454 | $452 | 216,920 | $— | $78,092 | $(75,131) | $6,713 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.